ICER Releases Report on Ovarian Cancer Inhibitors

The Institute for Clinical and Economic Review is accepting public comments on its Draft Evidence Report for olaparib, niraparib and rucaparib, all of which are poly ADP-ribose polymerase inhibitors used in ovarian cancer treatment.

According to a press release issued by ICER, the report will be open to public comment until 5 p.m. EST August 9.

“ICER is committed to engaging with all stakeholders in a thorough and transparent manner,” ICER said in a press release. “Before completing this Draft Evidence Report, ICER reached out to key stakeholders, including patient groups, clinical experts and the manufacturers of the drugs to engage them in the process.”

A Draft Scoping Document was also open to public comments before the report’s release, which included input from patients, clinicians, manufacturers and other stakeholders.

More Links

Support & Contact

About

Stay Connected

HealthEconomics.Com is the world’s most comprehensive and credible CONNECTED COMMUNITYTM that serves as the global link to the health economics & outcomes research (HEOR) and pharma market access stakeholder communities.